Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effisayil™ 1:Multi-center, Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety and Tolerability of a Single Intravenous Dose of Spesolimab (BI 655130) in Patients With Generalized Pustular Psoriasis (GPP) Presenting With an Acute Flare of Moderate to Severe Intensity

NCT03782792 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03782792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03782792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effisayil™ 1:Multi-center, Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety and Tolerability of a Single Intravenous Dose of Spesolimab (BI 655130) in Patients With Generalized Pustular Psoriasis (GPP) Presenting With an Acute Flare of Moderate to Severe Intensity
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2019
Completion date
January 5, 2021
Enrollment
53 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

generalized pustular psoriasis